Published in Am J Hematol on September 01, 1988
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth. J Cancer Res Clin Oncol (2012) 0.77
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol (2014) 0.77
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol (1999) 2.05
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76
Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58
Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med (1984) 1.57
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys (1998) 1.56
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med (1987) 1.55
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Cancer immunotherapy. Can Med Assoc J (1979) 1.54
Expression of interleukin-6 in Castleman's disease. Hum Pathol (1993) 1.53
Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood (1994) 1.52
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol (1996) 1.46
Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer (1991) 1.45
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
Melphalan therapy for plasma cell myeloma. Blood (1968) 1.43
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol (2001) 1.42
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst (1977) 1.40
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood (2000) 1.39
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci U S A (2001) 1.37
Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood (1988) 1.36
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant (2006) 1.35